北京商报讯（记者 王寅浩 宋雨盈）1月30日，科兴制药发布2025年业绩预告，预计2025年实现归属于母 公司所有者的净利润为1.35亿—1.75亿元，同比增加328.83%—455.89%。预计归属于母公司所有者的扣 除非经常性损益的净利润为5000万—7000万元，同比增加41.83%—98.56%。 根据公告，2025年，科兴制药积极开拓海外市场，实现了海外收入增长，推动营收持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。 ...

每经AI快讯，君实生物1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利 润-8.73亿元左右，与上年同期相比亏损减少约4.08亿元左右，同比亏损减少31.85%左右。业绩变动主要 原因是，报告期内，公司营业收入增长，主要系商业化药品的销售收入与上年同期相比有所增长。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

本年度，公司核心产品泰它西普、维迪西妥单抗国内销售收入实现快速增长，成为业绩核心增长引擎； 同时，公司成功达成重磅合作，授予Vor Biopharma Inc泰它西普除大中华区以外全球范围内的独家开发 与商业化权利，技术授权收入大幅增加，部分海外研发投入由授权方承担。此外，公司通过优化管理、 迭代生产工艺等举措，降低了产品单位生产成本，提升了产品毛利率，另外，销售费用率明显下降。综 合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。 格隆汇1月30日丨荣昌生物(688331.SH)公布，经公司财务部门初步测算，预计2025年度营业收入约 325,000万元，与上年同期相比，将增加收入约153,314万元，同比增加约89%。公司预计2025年度实现 归属于母公司所有者的净利润约71,600万元，与上年同期相比，实现扭亏为盈。公司预计2025年度归属 于母公司所有者扣除非经常性损益后的净利润约7,850万元，与上年同期相比，实现扭亏为盈。 ...

每经记者|章光日 每经编辑|何小桃 吴永久 1月30日早上，新诺威（SZ300765，市值546亿元）迎来新任总经理和新任董事会秘书，二人皆为"90后"。不过，资本市场对此反应并不友好，新诺威早 盘股价最大跌幅一度达到18%。而不久前，新诺威还发布了2025年年度业绩预亏公告，净利润较2024年同期下降416%至575%。 新任总经理和董秘皆为"90后" 1月30日，新诺威发布关于变更公司总经理、董事会秘书及证券事务代表的公告。该公告显示，姚兵申请辞去公司总经理职务，戴龙申请辞去公司董事会 秘书及证券事务代表职务，与此同时，公司董事会同意聘任戴龙担任公司总经理，同意聘任徐雯担任公司董事会秘书及证券事务代表。 而新诺威新任总经理戴龙和新任董事会秘书皆为"90后"。 戴龙1992年6月出生，本科学历，2016年12月加入新诺威，历任公司财务经理、证券事务代表、董事会秘书。目前，戴龙还担任新诺威的董事和财务总 监。新诺威2024年年报显示，尽管身兼数职，但戴龙2024年从公司获得的税前报酬总额仅为22.32万元。 徐雯1990年4月出生，硕士学历，从2024年5月开始担任新诺威的董事。不过，新诺威2024年年报显示 ...

每经AI快讯，首药控股1月30日晚间发布2025年年度业绩快报，营业收入866.76万元，同比增加 119.88%；归属于上市公司股东的净利润亏损约1.29亿元；基本每股收益亏损0.87元。 （记者 曾健辉） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 每经AI快讯，微芯生物1月30日晚间发布公告称，公司于2026年1月30日收到股东天府清控的《关于被 冻结股份已解冻的告知函》，获悉其所持公司股份被司法冻结的约821万股已全部解冻。 ...

Core Viewpoint - Changchun Gaoxin (000661.SZ) expects a significant decline in net profit attributable to shareholders for 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 150 million to 220 million yuan for 2025, indicating a substantial decline from the previous year [1] - The expected decline in profit is attributed to increased research and development expenses as the company advances its product pipeline [1] Group 2: Business Focus and Strategy - The company continues to focus on traditional strengths in endocrine metabolism and women's health, while also exploring innovative directions related to oncology, respiratory, and immune-related products [1] - Ongoing R&D efforts are aimed at developing differentiated products with global market potential, with several products entering clinical stages [1] Group 3: Industry Challenges - The company faces intensified competition within the industry, which is expected to impact its financial performance [1] - Changchun Baike Biotechnology Co., a subsidiary, is projected to incur losses in 2025, contributing to the overall decrease in the company's performance [1]

Core Viewpoint - Huaxi Biological (688363) expects a significant increase in net profit for 2025, projecting a range of 270 million to 320 million yuan, representing a year-on-year growth of 54.93% to 83.63% [1] Group 1: Financial Performance - The company anticipates a net profit of 270 million to 320 million yuan for 2025, indicating a substantial increase compared to the previous year [1] - The projected growth is attributed to systematic optimization of organizational structure, functional integration, and upgraded operational models [1] Group 2: Operational Efficiency - The company is transitioning from "scale expansion" to "quality growth," aiming to enhance operational efficiency and optimize costs [1] - Management expenses are expected to decrease by over 10% year-on-year in 2025, providing foundational support for profit growth [1] Group 3: Business Strategy - The company focuses on professional development and continues to optimize its business structure and resource allocation [1] - Sales expenses are projected to decline by over 30% year-on-year, contributing to sustained improvement in profitability despite revenue pressures [1]

北京商报讯（记者 丁宁）1月30日晚间，荣昌生物（688331）发布2025年业绩预告显示，经公司财务部 门初步测算，预计2025年营业收入约32.5亿元，同比增加约89%。预计2025年实现归属净利润约7.16亿 元，与上年同期相比，实现扭亏为盈。 荣昌生物表示，报告期内，公司核心产品泰它西普、维迪西妥单抗国内销售收入实现快速增长，成为业 绩核心增长引擎；同时，公司成功达成重磅合作，授予Vor BiopharmaInc泰它西普除大中华区以外全球 范围内的独家开发与商业化权利，技术授权收入大幅增加，部分海外研发投入由授权方承担。此外，公 司通过优化管理、迭代生产工艺等举措，降低了产品单位生产成本，提升了产品毛利率，另外，销售费 用率明显下降。综合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。 ...

Core Viewpoint - Frontier Biotech (688221.SH) expects to achieve a revenue of approximately 140 million to 145 million yuan in 2025, representing a year-on-year increase of 8.13% to 11.99%, primarily driven by sales of its innovative HIV drug Aikening® (generic name: Abacavir), the agency product Viread® (Tenofovir Disoproxil Fumarate), and the newly approved far-infrared therapy patch (Xiaoyan Yipian®) [1] Revenue Forecast - The company anticipates that its revenue for 2025 will be between 140 million and 145 million yuan, reflecting a growth of 8.13% to 11.99% compared to the previous year [1] - The revenue growth is mainly attributed to the sales of Aikening®, Viread®, and the newly approved far-infrared therapy patch [1] Profit Forecast - The company projects a net loss attributable to shareholders of approximately 255 million to 290 million yuan for 2025, which is an increase in loss of about 53.62 million to 88.62 million yuan [1] - This increase in loss is primarily due to the absence of investment income from the disposal of subsidiary equity, which generated 71.84 million yuan in 2024 [1] - The expected net loss attributable to shareholders after excluding non-recurring gains and losses is estimated to be between 288 million and 323 million yuan, reflecting a reduction in loss of approximately 4.31 million to 39.31 million yuan, mainly due to revenue growth and reduced operating expenses [1]